What Is Stage 1 of Asthma? Complete 2026 Guide to Intermittent Asthma (NAEPP + GINA)

Stage 1 of asthma is called intermittent asthma. According to the National Asthma Education and Prevention Program (NAEPP) EPR-3 classification, it is the mildest stage in which patients experience daytime symptoms ≤2 days/week, night-time awakenings ≤2 times/month, no interference with normal activity, a FEV1 ≥80% predicted, a normal FEV1/FVC ratio, and 0–1 exacerbations per year. It is the first and least severe step on the classical asthma severity ladder and often responds beautifully to on-demand reliever inhaler or low-dose ICS-formoterol as per GINA 2024.

Author: Dr Sagar Rajkuwar, MS-ENT Specialist, Nashik, Maharashtra, India

🌐 www.entspecialistinnashik.com

📌 Table of Contents

1. Introduction
2. What Is Stage 1 of Asthma? — Definition
3. NAEPP vs GINA — Two Different Classifications
4. Full NAEPP Criteria for Stage 1 (Intermittent) Asthma
5. Pathophysiology of Early-Stage Asthma
6. Common Symptoms of Stage 1 Asthma
7. Common Triggers in Stage 1 Patients
8. How Stage 1 Asthma Is Diagnosed
9. Spirometry, FeNO & Peak Flow in Stage 1
10. Children vs Adults: Differences in Stage 1
11. Treatment of Stage 1 Asthma (GINA 2024 Step 1)
12. Why Even “Mild” Asthma Needs Controller Therapy
13. Can Stage 1 Progress to Stage 2–4?
14. Lifestyle & Natural Measures
15. Red-Flag Symptoms — When to Seek Help
16. Prognosis & Long-Term Outlook
17. Statistics & Epidemiology (2025–2026)
18. Myths vs Facts about Mild Asthma
19. Summary / Key Takeaways
20. Frequently Asked Questions
21. Conclusion
22. References

1. Introduction

Approximately 262 million people live with asthma worldwide, and the WHO estimates nearly half fall into the mildest category — what clinicians call intermittent or Stage 1 of asthma. Understanding this earliest stage matters because early recognition can prevent progression to more severe, steroid-dependent disease. This 2026 evidence-based guide, written by Dr Sagar Rajkuwar, draws from NAEPP 2007 EPR-3, the 2020 NAEPP Focused Updates, the Global Initiative for Asthma (GINA) 2024, NHS, CDC, and peer-reviewed literature.

🎥 Watch Educational Video

👉 YouTube Channel: http://www.youtube.com/@healthuseful8539/

2. What Is Stage 1 of Asthma? — Definition

Stage 1 of asthma, formally labelled intermittent asthma by the NAEPP EPR-3, is defined by infrequent, mild symptoms that do not interfere with daily life and preserve near-normal pulmonary function. Patients may go days or even weeks without symptoms, use their short-acting β2-agonist (SABA) rarely, and show a normal spirometry. Importantly, “mild” does not mean “safe” — according to GINA, 30–37% of adults who die from asthma attacks had intermittent or mild disease.

Key feature:

Symptoms are present but infrequent, and lung function is preserved between attacks.

3. NAEPP vs GINA — Two Different Classifications

Two major guidelines classify asthma differently, and both are relevant to Stage 1 of asthma:

• NAEPP (United States) uses 4 severity stages: Intermittent (Stage 1), Mild Persistent (Stage 2), Moderate Persistent (Stage 3), Severe Persistent (Stage 4).
• GINA (International) uses 5 treatment steps rather than severity stages. GINA Step 1 roughly corresponds to NAEPP Stage 1.

GINA explicitly discourages labelling adults as “intermittent” because even mild cases carry attack risk — but the severity classification remains clinically useful for initial assessment.

4. Full NAEPP Criteria for Stage 1 (Intermittent) Asthma

To be classified at Stage 1 of asthma, ALL of the following must be true before controller therapy is started:

If any one criterion is exceeded, the classification jumps to Stage 2 (Mild Persistent).

5. Pathophysiology of Early-Stage Asthma

Even in Stage 1 of asthma, the underlying biology is already active. Key features include chronic airway inflammation, eosinophilic infiltration, goblet-cell hyperplasia, Th2 cytokine release (IL-4, IL-5, IL-13), bronchial hyperresponsiveness, and reversible bronchoconstriction. Peer-reviewed studies in the Lancet and NEJM confirm that airway remodeling — subepithelial fibrosis, smooth-muscle hypertrophy, and basement-membrane thickening — may begin years before symptoms become persistent. This is the reason modern GINA guidance now recommends inhaled corticosteroid use even at Step 1.

6. Common Symptoms of Stage 1 Asthma

• Occasional wheezing, usually in the morning or at night
• Brief chest tightness after exercise, cold air, or dust exposure
• Dry, nagging cough, often worse at night
• Shortness of breath during physical exertion
• Allergy-triggered episodes (pollen, pet dander, dust mites)
• Mild dyspnea that resolves within minutes of SABA use

Patients at Stage 1 of asthma often describe themselves as “fine most of the time,” which can delay diagnosis.

7. Common Triggers in Stage 1 Patients

• Allergens: dust mites, pollen, mold, cockroaches, pet dander
• Irritants: tobacco smoke, vaping, air pollution, perfumes
• Weather: cold or dry air, sudden temperature change, thunderstorms
• Exercise: especially outdoors in cold weather (exercise-induced bronchoconstriction)
• Infections: rhinovirus, influenza, RSV, COVID-19
• Occupational exposures: isocyanates, flour dust, latex
• Medications: NSAIDs (aspirin-exacerbated respiratory disease), β-blockers
• GERD and allergic rhinitis — often coexist and worsen control

8. How Stage 1 Asthma Is Diagnosed

Diagnosis of Stage 1 of asthma requires both clinical history and objective lung-function evidence. The GINA 2024 protocol is:

1. Variable respiratory symptoms (wheeze, cough, chest tightness, breathlessness)
2. Documented variable expiratory airflow limitation (via spirometry)
3. Positive bronchodilator reversibility: FEV1 increase ≥12% and ≥200 mL after SABA
4. Supportive tests: FeNO ≥25 ppb, peak flow variability >10%, bronchial challenge test

For a complete diagnostic workflow, see our full guide on How to Confirm Bronchial Asthma and the companion piece on blood tests for asthma.

9. Spirometry, FeNO & Peak Flow in Stage 1

• Spirometry: FEV1 ≥ 80% predicted, FEV1/FVC normal, but post-bronchodilator reversibility present
• FeNO: may be mildly elevated (25–50 ppb) indicating eosinophilic inflammation
• Peak expiratory flow (PEF): diurnal variability >10% supports diagnosis
• Methacholine challenge: useful when spirometry is normal; PC20 ≤8 mg/mL confirms hyperresponsiveness

A patient at Stage 1 of asthma may have completely normal spirometry on the day of visit — the challenge test or FeNO often confirms the diagnosis.

10. Children vs Adults: Differences in Stage 1

Children (≤11 years):

• Diagnosis often clinical; spirometry unreliable under age 5
• Use the Asthma Predictive Index (API)
• FEV1/FVC >85% considered normal
• Preferred reliever: SABA via spacer with mask

Adults:

• Spirometry mandatory
• GINA 2024 recommends low-dose ICS-formoterol as reliever even at Step 1
• Occupational history must be taken

11. Treatment of Stage 1 Asthma (GINA 2024 Step 1)

The GINA 2024 framework for Stage 1 of asthma gives two tracks:

Track 1 (preferred): ICS-formoterol as needed

• Low-dose budesonide-formoterol (e.g., 160/4.5 μg) taken only when symptoms occur
• Reduces severe exacerbations by up to 60% compared with SABA alone (SYGMA trials, NEJM 2018)

Track 2 (alternative): SABA + ICS whenever SABA is used

• Blue reliever inhaler salbutamol on demand
• Low-dose inhaled corticosteroid (ICS) such as budesonide 200 μg BD or fluticasone 100 μg BD, taken together with the SABA

SABA-only therapy is no longer recommended because it increases attack and death risk. For full treatment of all stages, see our Bronchial Asthma Treatment Guide.

12. Why Even “Mild” Asthma Needs Controller Therapy

Three landmark studies — START (Lancet 2003), SYGMA-1 & SYGMA-2 (NEJM 2018), and Novel-START (NEJM 2019) — proved that even intermittent asthma benefits from low-dose ICS. Benefits include fewer severe attacks, less lung-function decline, and lower mortality. This is why Stage 1 of asthma should never be managed with SABA alone in 2026.

13. Can Stage 1 Progress to Stage 2–4?

Yes. Without proper trigger control, allergen management, and anti-inflammatory therapy, 15–25% of intermittent cases progress to persistent disease within 5 years (ERS Monograph 2024). Risk factors for progression include smoking, obesity, uncontrolled allergic rhinitis, recurrent viral infections, and poor inhaler technique. Protective factors: timely ICS, trigger avoidance, and regular review.

14. Lifestyle & Natural Measures

• Stop smoking and avoid second-hand smoke
• Maintain BMI <25 — obesity triples attack risk
• Mediterranean diet rich in omega-3 and antioxidants
• Treat allergic rhinitis with intranasal steroid
• Annual influenza, pneumococcal, and COVID-19 vaccination
• Buteyko and pranayama breathing — supportive, not substitutes
• Reduce dust-mite exposure (mite-proof covers, HEPA filter)
• Vitamin D optimization — deficiency raises exacerbation risk

Patients at Stage 1 of asthma often get excellent long-term control when lifestyle changes combine with low-dose ICS.

15. Red-Flag Symptoms — When to Seek Help

• Reliever inhaler needed more than twice a week
• Night-time cough or wheeze more than twice a month
• Reliever no longer working as it used to
• Peak flow dropping below 80% of personal best
• Any ER visit or oral steroid course
• Breathlessness that limits exercise or sleep

Any of these means the patient is no longer at Stage 1.

16. Prognosis & Long-Term Outlook

With correct treatment, Stage 1 of asthma has an excellent prognosis. Most patients experience long periods of complete symptom freedom. Up to 30% of childhood intermittent asthma remits by late adolescence, although airway hyperresponsiveness may persist (Melbourne Asthma Study, Thorax 2021).

17. Statistics & Epidemiology (2025–2026)

• 262 million people worldwide live with asthma (WHO 2024)
• Asthma causes ~455,000 deaths annually, most preventable
• Approximately 50–60% of all asthmatics are classed as mild/intermittent
• India: ~35 million asthmatics; prevalence ~2.3% of adults (ICMR 2024)
• USA: 25 million asthmatics (CDC 2025), 8.7% of children
• UK: 5.4 million patients receiving treatment (Asthma + Lung UK 2024)

18. Myths vs Facts about Mild Asthma

• ❌ “Mild asthma can’t kill.” — ✅ 30–37% of asthma deaths occur in mild disease (BTS National Review of Asthma Deaths).
• ❌ “Only use the inhaler during an attack.” — ✅ Modern guidelines recommend ICS even for mild asthma.
• ❌ “You’ll outgrow it.” — ✅ Many children remit but airway hyperresponsiveness often persists.
• ❌ “Steroid inhalers are dangerous.” — ✅ Low-dose ICS is extremely safe; side effects minimal.
• ❌ “If spirometry is normal, you don’t have asthma.” — ✅ Many intermittent patients have normal baseline spirometry; FeNO or challenge test clarifies.

19. Summary / Key Takeaways

• Stage 1 of asthma = intermittent asthma under NAEPP; GINA Step 1 equivalent.
• Symptoms ≤2 days/week, nights ≤2/month, FEV1 ≥80%, 0–1 exacerbations/year.
• Still involves genuine airway inflammation — treat it, don’t ignore it.
• GINA 2024 preferred reliever: low-dose ICS-formoterol as needed.
• SABA-only therapy is obsolete.
• Trigger avoidance, vaccination, weight management and allergic rhinitis treatment are essential.
• Even mild asthma can cause fatal attacks — always carry a reliever.

20. Frequently Asked Questions

What exactly is Stage 1 of asthma?

It is intermittent asthma under NAEPP: symptoms ≤2 days/week, nocturnal awakenings ≤2/month, no activity limitation, FEV1 ≥80%, and 0–1 exacerbations/year.

Is Stage 1 asthma dangerous?

Usually not, but it can still cause fatal attacks. Up to 37% of asthma deaths occur in mild disease. Always carry a reliever inhaler.

Does Stage 1 asthma require daily medication?

GINA 2024 recommends low-dose ICS-formoterol as needed (not necessarily daily), which both relieves symptoms and controls inflammation.

Can Stage 1 asthma be cured?

Asthma is not curable, but intermittent asthma can be fully controlled. Some children remit in adolescence. Read our detailed guide: Can Bronchial Asthma Be Cured?

Can Stage 1 progress to severe asthma?

Yes — about 15–25% progress to persistent disease within 5 years without proper management.

What triggers Stage 1 asthma?

Dust mites, pollen, cold air, exercise, viral infections, smoke, strong odours, NSAIDs, and GERD.

Do I need a spacer for Stage 1 asthma?

Yes — a spacer improves lung deposition by up to 10× and reduces side effects.

How do I know if I have Stage 1 or Stage 2 asthma?

Count symptom days, nights, and reliever uses in a typical month. Exceeding any one Stage 1 threshold means Stage 2.

Does Stage 1 asthma show on a chest X-ray?

No. Chest X-rays are usually normal in intermittent asthma; they are done to rule out other conditions.

What’s the best diet for Stage 1 asthma?

A Mediterranean-style diet with omega-3 fish, fruits, vegetables, and whole grains; limit processed food and sulfite-rich wines.

21. Conclusion

Understanding Stage 1 of asthma is the first and most important step in long-term airway health. Although “intermittent” sounds reassuring, the underlying eosinophilic inflammation and bronchial hyperresponsiveness are already present. Modern GINA 2024 and NAEPP guidance recommends low-dose inhaled corticosteroid-formoterol as needed, trigger control, vaccination, and regular review. With these simple measures, most patients at Stage 1 enjoy full, symptom-free lives and avoid progression to more severe disease.

📞 ENT Consultation & Surgery

Dr. Sagar Rajkuwar (MS-ENT)
Prabha ENT Clinic, Ambad, Nashik

📱 7387590194 | 9892596635
🌐 www.entspecialistinnashik.com

📲 For Health-Related Articles & Videos

🔹 Facebook: https://www.facebook.com/positivemind.healthcare
🔹 YouTube: http://www.youtube.com/@healthuseful8539/

Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified doctor and follow a personalised written asthma action plan. In an emergency, call local emergency services immediately.

22. References

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. NHLBI, 2007; Focused Updates 2020.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024. https://ginasthma.org
3. WHO. Asthma Fact Sheet 2024. https://www.who.int/news-room/fact-sheets/detail/asthma
4. CDC. Most Recent National Asthma Data. https://www.cdc.gov/asthma
5. NHS. Asthma — Overview. https://www.nhs.uk/conditions/asthma
6. O’Byrne PM et al. Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. SYGMA-1. NEJM 2018;378:1865-1876.
7. Bateman ED et al. As-Needed Budesonide–Formoterol vs Maintenance Budesonide in Mild Asthma. SYGMA-2. NEJM 2018;378:1877-1887.
8. Hardy J et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever in adults with mild to moderate asthma (PRACTICAL). Lancet 2019;394:919-928.
9. Pauwels RA et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. START. Lancet 2003;361:1071-1076.
10. British Thoracic Society / SIGN. BTS/SIGN British Guideline on the Management of Asthma. 2019 (updated 2024).
11. Royal College of Physicians. National Review of Asthma Deaths (NRAD). 2014.
12. ICMR. India State-Level Disease Burden Initiative — Respiratory Diseases. 2024.

Related Reading

• What Is the 4x4x4 Rule for Asthma?
• At What Age Does Asthma Start?
• Can Bronchial Asthma Be Cured?
• How to Confirm Bronchial Asthma
• Blood Tests for Asthma
• Main Causes of Bronchial Asthma
• How to Treat Bronchial Asthma
• Bronchial Asthma Symptoms
• Difference Between Asthma and Bronchial Asthma